跳转到主内容

非常抱歉,我们不完全支持您的浏览器。如果您可以选择,请升级到较新版本或使用 Mozilla Firefox、Microsoft Edge、Google Chrome 或 Safari 14 或更高版本。如果您无法进行此操作且需要支持,请将您的反馈发送给我们。

全新设计的官网为您带来全新体验,期待您的反馈(在新的选项卡/窗口中打开)

Elsevier
通过我们出版

Versus Arthritis

Elsevier has established a funding body agreement with Versus Arthritis(在新的选项卡/窗口中打开) to help authors publishing in Elsevier journals comply and to facilitate a successful implementation of their policy. Details about how to comply are outlined below.

Agreement

Versus Arthritis requires grantees, from the 1st January 2007, to pursue open access publishing and are required to submit an electronic copy of the final manuscript of their research papers to PubMed Central (PMC) and PMC’s linked sister repository Europe PubMed Central (Europe PMC) within six months of publication.

Versus Arthritis-funded authors are free to choose the gold open access option offered by Elsevier. Authors can comply by publishing in either an Elsevier open access journal or in a subscription journal with an open access option. This includes journals published by The Lancet.

Gold open access

To provide open access, a publication fee needs to be met for each article published open access. For information about specific open access publication fees, please refer to the individual journal homepage and guide for authors. Versus Arthritis will meet these costs only if the author’s institution is unable to.

Upon publication, Elsevier will supply the final published article to Europe PMC on the author’s behalf. This will then be automatically mirrored on the PMC site. All articles published open access have permitted reuse which is determined by the author's choice of user license.

Green open access

Versus Arthritis-funded authors who do not have funds available for gold open access can self-archive their accepted manuscript on Europe PMC after the embargo period for their specific journal has expired. Posted accepted author manuscripts must include a link back to the original and final published articles.

Help and support